Journal of Diabetes Research最新文献

{"title":"Revealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation.","authors":"Meng Tian, Junchao Wu, Qian Du, Jiale Han, Meng Yang, Xiang Li, Mingzhu Li, Xiaofeng Ding, Yeqiang Song","doi":"10.1155/jdr/4656485","DOIUrl":"https://doi.org/10.1155/jdr/4656485","url":null,"abstract":"<p><p><b>Background:</b> Shikonin (SHK) possesses extensive pharmacological effects including antimicrobial and anti-inflammatory properties for diabetic wound (DW), while its molecular mechanism remains to be clarified. In this study, we investigated the potential mechanisms of SHK in treating DW by combining network pharmacology and in vitro experiments. <b>Methods:</b> We obtained potential targets for SHK and DW from the publicly available database. Based on the interaction network and conducting GO and KEGG pathway enrichment analysis, we constructed a target pathway network to explore the relationship between SHK and DW. To validate the mechanism of SHK, we established an in vitro experimental model. <b>Results:</b> Sixty intersecting targets between SHK and DW were obtained, and the top 10 targets of the protein-protein interaction (PPI) network included AKT1, SRC, EGFR, CASP3, MMP9, PPARG, ESR1, ANXA5, MMP2, and JAK2. Based on target-pathway networks, the PI3K-AKT signaling pathway was found to be a signaling pathway with low <i>p</i> value in enrichment analysis. In vitro experiments revealed that SHK significantly promoted angiogenesis. Meanwhile, SHK could inhibit the high glucose-induced human umbilical vein endothelial cell dysfunction through regulating the PI3K-AKT pathway. <b>Conclusion:</b> This study initially revealed the molecular mechanism of SHK in DW by multitarget and multipathway. The PI3K-AKT signaling pathway, MAPK signaling pathway, and AGE-RAGE signaling pathways may be the main pathways of SHK in treating DW.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"4656485"},"PeriodicalIF":3.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint Effects of Physical Activity and Body Mass Index on Prevalent Diabetes in a Nationally Representative Sample of 1.9 Million US Adults.","authors":"David Abernethy, Jason Bennie, Toby Pavey","doi":"10.1155/jdr/7466757","DOIUrl":"https://doi.org/10.1155/jdr/7466757","url":null,"abstract":"<p><p><b>Aim:</b> To investigate the joint effects of physical activity (PA) and body mass index (BMI) on prevalent diabetes mellitus in a nationally representative sample of US adults. <b>Materials and Methods:</b> Data were pooled from five US Behavioral Risk Factor Surveillance System (BRFSS) surveys from 2011 to 2019. Cross-sectional associations between independent and combined PA and BMI status and diabetes were analysed using Poisson's log-linear regression with a robust-error variance, reported by adjusted prevalence ratios (APRs). These models were adjusted for relevant sociodemographic, behavioral, and health-related factors. <b>Results:</b> Data was available for 1,913,732 individuals (≥ 18 years). Considering individuals highly active and with normal weight as the reference group, there was an association between decreasing levels of PA and increasing BMI and diabetes prevalence. APRs ranged from APR = 1.09 (nonactive, normal weight group; 95% CI = 1.09-1.09), 1.67 (nonactive, overweight group; 95% CI = 1.67-1.67), 2.23 (nonactive, Class I obesity group; 95% CI = 2.23-2.23), 2.71 (nonactive, Class II obesity group; 95% CI = 2.71-2.71), and 3.17 (nonactive, Class III obesity group; 95% CI = 3.16-3.17). <b>Conclusions:</b> BMI appears to be a substantially larger predictor of diabetes compared to PA in a large population-level sample of US adults. PA provided modest reductions in the prevalence of diabetes but did not attenuate the detrimental impact of overweight and increasing levels of obesity on diabetes prevalence.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"7466757"},"PeriodicalIF":3.6,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphocyte Subsets and Cytokine Changes in Women With Gestational Diabetes Mellitus: A Systematic Review.","authors":"Wang Yu, Huang Miao, Yunhui Gong","doi":"10.1155/jdr/3494697","DOIUrl":"https://doi.org/10.1155/jdr/3494697","url":null,"abstract":"<p><p><b>Introduction:</b> Gestational diabetes mellitus (GDM) is a major health concern during pregnancy, affecting both the mother and the baby. Immune system alterations, particularly changes in lymphocyte subsets and cytokine profiles, have been associated with the pathophysiology of various metabolic disorders, including diabetes. This study is aimed at systematically reviewing the literature on the changes in lymphocyte subsets and cytokines in GDM. <b>Methods:</b> In this systematic review, we applied specific criteria to select observational studies (such as case-controls, cross-sectionals, or cohorts) that focused on pregnant women. We performed an extensive search across electronic databases, including Web of Science, Scopus, PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Google Scholar, from January 1, 2010, to March 20, 2024. <b>Results:</b> A total of 19 articles, with 2517 participants (1128 with GDM and 1389 without GDM), were included in the qualitative synthesis. Due to high heterogeneity among the articles, a meta-analysis was not conducted. The studies assessed 35 different lymphocyte subsets or proportions. The most commonly assessed subsets were CD3+ T cell (five articles, mostly no difference between GDM and non-GDM), CD4+ T cell (five articles with contradictory results), CD8+ T cell (four articles with contradictory results), B cell and NK cell (three articles, mostly no difference between GDM and non-GDM), and Tregs (three articles with contradictory results). Additionally, 32 cytokines or proportions were assessed in the studies. The most commonly assessed cytokines were IL-6 (eight articles, higher or similar levels in GDM compared to non-GDM), TNF-<i>α</i> (seven articles, mostly higher or similar levels in GDM compared to non-GDM), IL-10 (six articles, mostly no difference between GDM and non-GDM), IL-2 (three articles, mostly no difference between GDM and non-GDM), and IFN-<i>γ</i> (three articles with contradictory results). <b>Conclusion:</b> According to the results, there were no significant changes in CD3+ T cells, B cells, NK cells, IL-10, and IL-2 in GDM. However, the levels of IL-6 and TNF-<i>α</i> were higher or similar in GDM compared to non-GDM. The changes of other lymphocyte subsets and cytokines in GDM remained unclear.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"3494697"},"PeriodicalIF":3.6,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Smartphone Application-Based Self-Management Interventions Compared to Face-to-Face Diabetic Interventions for Pregnant Women With Gestational Diabetes Mellitus: A Meta-Analysis.","authors":"Thet Nu Khin, Wen Wei Ang, Ying Lau","doi":"10.1155/jdr/4422330","DOIUrl":"https://doi.org/10.1155/jdr/4422330","url":null,"abstract":"<p><p><b>Background:</b> Face-to-face diabetic interventions (FFIs) are the gold standard for diabetic care, and smartphone application (app)-based self-management interventions (SBIs) can be a potential alternative. A few previous reviews compared the effects of both practices. <b>Objectives:</b> This study is aimed at (1) comparing the effectiveness of FFIs and SBIs on maternal and neonatal outcomes in pregnant women with gestational diabetes mellitus (GDM) and (2) exploring potential covariates affecting those outcomes. <b>Methods:</b> Randomized controlled trials (RCTs) were retrieved from PubMed, EMBASE, CINAHL, Cochrane Library, Scopus, and Web of Science from inception to January 15, 2024. Meta-analyses, subgroup analyses, and metaregression analyses were conducted using the <i>R</i> software package <i>meta</i>, Version 4.3.1. Cochrane risk of bias Version 2 (RoB2) and grading of recommendations, assessment, development, and evaluation (GRADE) criteria were employed to appraise the quality of studies and certainty of outcomes. <b>Results:</b> We selected 15 RCTs from 2505 women with GDM across 11 countries for this review. The meta-analyses revealed that women in the SBIs can significantly reduce gestation weight gain (<i>t</i> = -2.45, <i>p</i> = 0.04) and macrosomia (<i>t</i> = -3.35, <i>p</i> = 0.02) when compared to those in the FFIs. We observed a higher likelihood of cesarean delivery when using generic apps (RR = 1.12, 95% confidence interval (CI): 0.59, 2.13) than GDM-specific apps (RR = 0.82, 95% CI: 0.64, 1.06). There was similar fasting plasma glucose, 2-h postprandial plasma glucose, hemoglobin A1c (HbA1c), cesarean section delivery rate, neonatal birthweight, large for gestational age, neonatal hypoglycemia, and neonatal intensive care unit admission between SBIs and FFIs. More than half (52%) were rated low risk based on RoB2. According to the GRADE criteria, very low to moderate evidence was found. <b>Conclusions:</b> SBIs can be considered an alternative management method for women with GDM to reap the benefits of smartphone apps. More high-quality RCTs are required to reaffirm the findings.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"4422330"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Association Between Cholesterol-Lowering Drugs and Diabetic Microvascular Complications: A Drug-Target Mendelian Randomization Study.","authors":"Bo Yang, Bo Yao, Qu Zou, Sicheng Li, Shun Yang, Mengxue Yang","doi":"10.1155/jdr/3661739","DOIUrl":"https://doi.org/10.1155/jdr/3661739","url":null,"abstract":"<p><p><b>Background:</b> It remains unclear whether cholesterol-lowering therapy can reduce the incidence of microvascular complications in patients with diabetes. We aim to explore the potential causal relationship between three common types of cholesterol-lowering drugs and diabetic microvascular complications through drug-target Mendelian randomization (MR) study, laying the groundwork for the development of new medications. <b>Methods:</b> In this study, we collected single nucleotide polymorphisms (SNPs) associated with HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) inhibitors, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, and NPC1L1 (Niemann-Pick C1-Like 1) inhibitors from published genome-wide association study statistics. Subsequently, drug-target MR analyses were performed to investigate the effects of these inhibitors on low-density lipoprotein cholesterol (LDL-C) level-mediated microvascular complications in diabetes mellitus. Coronary atherosclerosis as a positive control. Primary outcomes included diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy from the FinnGen Consortium. <b>Results:</b> The MR analysis revealed significant associations between HMGCR inhibition and increased risks of diabetic nephropathy (OR [95%confidence interval (CI)] = 1.88 [1.50, 2.36], <i>p</i> = 5.55 × 10^-8), retinopathy (OR [95%CI] = 1.86 [1.54, 2.24], <i>p</i> = 6.28 × 10^-11), and neuropathy (OR [95%CI] = 2.63 [1.84, 3.75], <i>p</i> = 1.14 × 10^-7) using the inverse variance weighted method. PCSK9 inhibitors have been associated with an increased risk of diabetic nephropathy (OR [95%CI] = 1.30 [1.07, 1.58], <i>p</i> = 0.009) and diabetic neuropathy (OR [95%CI] = 1.40 [1.15, 1.72], <i>p</i> = 0.001); NPC1L1 inhibitors significantly reduce the incidence of diabetic retinopathy (OR [95%CI] = 0.48 [0.28, 0.85], <i>p</i> = 0.01). The coronary heart disease as positive control. <b>Conclusions:</b> The findings show that HMGCR inhibitors and PCSK9 inhibitors may significantly increase the risk of diabetic microvascular complications. However, NPC1L1 inhibitors may provide protection against diabetic retinopathy.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"3661739"},"PeriodicalIF":3.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between ABCG1/TCF7L2 and Type 2 Diabetes Mellitus: An Intervention Trial Based on a Case-Control Study.","authors":"Yinxia Su, Bo Shang, Xiaoyuan Hu, Zhihao Zhang, Li Wang, Kun Luo, Hua Yao, Xiangtao Liu, Yaoqin Lu, Sheng Jiang","doi":"10.1155/jdr/9356676","DOIUrl":"https://doi.org/10.1155/jdr/9356676","url":null,"abstract":"<p><p><b>Background and Objective:</b> Type 2 diabetes mellitus (T2DM) is the result of both genetic and environmental factors. Environmental factors may contribute to the occurrence and development of T2DM by influencing epigenetic modification. The objective of this study was to explore the potential functions of two SNP-CG sites (rs7901695 of TCF7L2 and cg06500161 of ABCG1) that are most strongly associated with T2DM. Given that Uyghur population has been less studied, we conducted an intervention trial in Uyghur people to provide evidence for personalized health management of T2DM in them. <b>Methods:</b> From May to July 2022, 320 patients with T2DM and 332 patients without T2DM were treated with dietary pagoda-based health education intervention. The demographic data were collected before intervention and basic physical biochemical indexes before and after intervention by questionnaire and physical biochemical examination. SNP typing was performed by the TaqMan-MGB probe method, and gene methylation was detected by the pyrosequencing method. <b>Results:</b> The rs7901695 genotype difference of TCF7L2 was statistically significant between the case group and the control group (<i>p</i> < 0.05). After adjusting for covariates (smoking, alcohol consumption, exercise, fasting blood glucose (FPG), obesity, and hypertension), the genotype of rs7901695 in the TCF7L2 gene was associated with genetic susceptibility to T2DM in additive (TC vs. TT,<i>p</i> = 0.047; CC vs. TT,<i>p</i> = 0.010), dominant (<i>p</i> = 0.015), and recessive (<i>p</i> = 0.039) models. Before intervention, there were significant differences in the intake of water between the case group and the control group (<i>p</i> < 0.05). After intervention, there was statistical significance in the intake of coarse grains, fruits, aquatic products, eggs, dairy products, soy products, nuts, edible oils, and water between the case group and the control group (<i>p</i>s < 0.05). Logistic regression analysis showed that methylation of the ABCG1 gene was correlated with T2DM susceptibility after adjustment of covariable before intervention (<i>p</i> = 0.015, odds ratio (OR): 1.023; 95% confidence interval (CI): 1.004~1.041) but not after intervention. Generalized multifactor dimensionality reduction (GMDR) showed that the rs7901695 locus of the TCF7L2 gene and the cg06500161 locus of the ABCG1 gene had interaction with hypertension, dyslipidemia, abdominal obesity, and obesity and also had interaction with drinking, smoking, and exercise. <b>Conclusions:</b> The interaction of the rs7901695 site of the TCF7L2 gene and the cg06500161 site of the ABCG1 gene with environmental factors may increase the risk of T2DM in Uyghurs. The interaction between the cg06500161 site of the ABCG1 gene and environmental factors on T2DM varied with the intervention. The cg06500161 site of ABCG1 may serve as a biomarker to evaluate the effect of T2DM interventions.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"9356676"},"PeriodicalIF":3.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delving Into the Interaction Between Exercise and Diabetes on Methylation of the FKBP5 Gene.","authors":"Teng-Chi Yang, Jen Pi Tsai, Honda Hsu, Yen-Chung Chen, Yi-Chia Liaw, Shu Yi Hsu, Hao Jan Yang, Yung-Po Liaw","doi":"10.1155/jdr/1162708","DOIUrl":"10.1155/jdr/1162708","url":null,"abstract":"<p><p><b>Objective:</b> FKBP5 is a critical gene involved in regulating the hypothalamic-pituitary-adrenal (HPA) axis and stress response. Aberrant DNA methylation at FKBP5 cytosine-phosphate-guanine (CpG) sites, such as cg22363520 and cg00862770, has been implicated in mental health disorders and metabolic diseases, including Type 2 diabetes. Exercise is a modulator of DNA methylation and metabolic health. This study investigates the interaction between exercise, diabetes, and FKBP5 methylation at cg22363520 and cg00862770 and explores their implications for mental health and disease development. <b>Materials and Methods:</b> FKBP5 methylation levels at cg22363520 and cg00862770 were analyzed in a cohort stratified by diabetes and exercise. Multiple linear regression models assessed the main effects and interactions of exercise and diabetes on FKBP5 methylation, with further stratified analyses for site-specific effects. <b>Results:</b> Exercise and diabetes showed significant and site-specific effects on FKBP5 methylation at cg22363520 and cg00862770. At cg22363520, exercise significantly reduced methylation levels in nondiabetic participants (<i>β</i> = -0.00195, <i>p</i> = 0.0157), while no significant effect was observed in diabetic individuals. Conversely, at cg00862770, exercise significantly decreased methylation levels in diabetic participants (<i>β</i> = -0.00611, <i>p</i> = 0.0081), with no significant effect in the nondiabetic group. Diabetes itself was associated with increased FKBP5 methylation at both sites, particularly in individuals without regular exercise. Additionally, significant interaction effects between exercise and diabetes were identified for both cg22363520 (<i>p</i> = 0.0336) and cg00862770 (<i>p</i> = 0.0021), highlighting the interplay between metabolic status and physical activity in regulating FKBP5 methylation. <b>Conclusion:</b> This study demonstrates that the effects of exercise on FKBP5 methylation are site-specific and influenced by diabetes status. Exercise reduces methylation at cg22363520 in nondiabetics and at cg00862770 in diabetics, indicating its role in modulating epigenetic regulation of stress and metabolic pathways. These findings underscore the interplay between exercise, diabetes, and FKBP5 methylation, with potential implications for improving mental health and metabolic outcomes.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"1162708"},"PeriodicalIF":3.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Value of Glycemic Gap for Predicting Mortality in ICU in Patients With and Without Diabetes.","authors":"Ran Lou, Li Jiang, Meiping Wang, Tingting Wang, Quan Si, Weixue Su, Nan Wang, Yuyan Liu, Ting Chen, Qi Jiang, Bo Zhu","doi":"10.1155/jdr/4563928","DOIUrl":"10.1155/jdr/4563928","url":null,"abstract":"<p><p><b>Objective:</b> Dysglycemia is associated with poor outcomes; the actual status of dysglycemia of critically ill patients with diabetes should refer to background glycemia. We investigated the effect of difference between mean blood glucose and basic blood glucose upon outcomes. <b>Methods:</b> Glycated hemoglobin A1c (HbA1c) was detected within the first 24 h and converted to A1C-derived average glucose (ADAG) by the equation ADAG = [(HbA1c∗28.7) - 46.7]∗18^-1; blood glucose measurements were fourth per day during the first 7 days after admission; the mean blood glucose level (Mean), standard deviation (SD), and coefficient of variation (CV) were calculated. GAP were calculated as admission blood glucose and Mean minus ADAG, respectively. <b>Results:</b> Six hundred forty-nine patients were recruited and 428 survived at 28 days; 302 patients with diabetes had greater ADAG, blood glucose at admission (BG_adm), Mean, SD, CV, GAP, and hypoglycemia incidences. The GAP between Mean and ADAG had superior predictive power, which was decreased in patients with diabetes and increased in patients without diabetes. GAP7 was related to 28-day mortality; the death risk was decreased in patients with diabetes. Patients with lower GAP tended to survive. Nonsurvivors with diabetes suffered higher rate of hypoglycemia than survivors which was the opposite in patients without diabetes. <b>Conclusion:</b> The glycemic GAP between the mean level of blood glucose within the first 7 days in ICU and ADAG was independently associated with 28-day mortality of critically ill patients, which was different between patients with and without diabetes. Hypoglycemia in patients with diabetes should be a concern.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"4563928"},"PeriodicalIF":3.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should I Take Prediabetes Seriously or Not: A Qualitative Study on People's Perceptions of Prediabetes.","authors":"Katri Harcke, Marit Graue, Timothy Charles Skinner, Christina B Olsson, Dan Grabowski, Nouha Saleh-Stattin","doi":"10.1155/jdr/8063481","DOIUrl":"10.1155/jdr/8063481","url":null,"abstract":"<p><p>It is critical to ensure that lifestyle change programs are tailored to the person with prediabetes needs and wishes. However, programs that are carried out in research settings to delay or prevent Type 2 diabetes in people with prediabetes do not translate easily to everyday settings. There is a need to explore further the perceptions of people with prediabetes about the condition and their role in self-management to better balance the content of intervention programs for prediabetes with the participants' life context and experience. For this purpose, we invited 21 persons with prediabetes from four primary healthcare centers in Region Stockholm, Sweden, for individual interviews. Transcripts were analyzed with qualitative content analysis. Two main themes were identified, <i>prediabetes: a condition between health and disease</i> and <i>I must manage prediabetes myself but need support</i>. This in-between state has a serious impact on the decisions that people with prediabetes make concerning self-management and behavioral changes. One of the main findings of this study highlights the importance of communicating the diagnosis of prediabetes clearly and the importance of preventive actions as this can trigger behavioral change. People with prediabetes in our study shed light on different needs for support to make and maintain behavioral change which requires a person-centered approach. This support was described internally, from family and peers, or externally from healthcare professionals. These results will be used in a codesign study where healthcare professionals and persons with prediabetes discuss the components of a person-centered model for a behavioral change intervention in primary healthcare.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"8063481"},"PeriodicalIF":3.6,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.","authors":"Alfredo Vozza, Sara Volpe, Carlo Custodero, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Alessandro Bergamasco, Gianfranco Antonica, Cosimo Tortorella, Giuseppina Piazzolla","doi":"10.1155/jdr/8182211","DOIUrl":"10.1155/jdr/8182211","url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is one of the most life-threatening complications of diabetes and a leading cause of chronic kidney disease. Glucagon-like peptide 1 receptor agonists (GLP1-RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2is) appear to improve renal outcome in patients with Type 2 diabetes (T2D). In this context, the renal resistive index (RRI) is a useful doppler measure to study DKD and predict its evolution. The aim of this work was to study the effect of treatment with GLP1-RA or SGLT2i on RRI and the relationship between RRI and glycometabolic parameters. One hundred forty-five patients with T2D were enrolled in the study and treated for 26 weeks with once-weekly GLP1-RA (38 patients with dulaglutide and 39 with semaglutide), SGLT2i (40 patients), or other therapies (28 control patients). Clinical, anthropometric, and hematochemical parameters and RRI were measured at baseline (T0) and after 6 months of treatment (T6). Changes at 6 months were studied and compared by treatment group. Patients were predominantly male (58.6%), overweight (93.0%) or frankly obese (60.0%), with hypertension (90.0%) and high (> 0.64) or pathological (> 0.7) RRI values (82.0% or 37.0%, respectively). At baseline, RRI correlated positively with age, fasting blood glucose, glycated hemoglobin (HbA1c), triglycerides, and albuminuria and negatively with estimated-glomerular filtration rate (e-GFR). At T6, patients treated with either GLP1-RA or SGLT2i showed a significant improvement in RRI but not in albuminuria or e-GFR, compared with homologous at baseline. In particular, RRI normalized in 32% and 30% of patients on therapy with GLP1-RA and SGLT2i, respectively, while remaining almost unchanged in controls. Notably, the RRI improvement was independent of age, gender, diabetes duration, and changes in BMI, waist circumference, HbA1c, and e-GFR. In conclusion, RRI can be used to detect early kidney damage and follow the evolution of DKD. GLP1-RA and SGLT2i improve RRI, demonstrating benefits on cardiovascular risk and renal outcomes.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"8182211"},"PeriodicalIF":3.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}